Novel Anti-Trop2 Nanobodies Disrupt Receptor Dimerization and Inhibit Tumor Cell Growth.

Autor: Deng, Junwen^1,2 (AUTHOR) 2021021179@qdu.edu.cn, Geng, Zhongmin^1,2 (AUTHOR) gzmin-qdu@qdu.edu.cn, Luan, Linli³ (AUTHOR) ll0527ll@163.com, Jiang, Dingwen³ (AUTHOR) jiangdingwen@auambio.com, Lu, Jian³ (AUTHOR) luj@noventi.com.cn, Zhang, Hanzhong^1,2 (AUTHOR) zhz17805982993@163.com, Chen, Bingguan³ (AUTHOR) chenbg@noventi.com.cn, Liu, Xinlin^1,2 (AUTHOR) lxl2021910024@qdu.edu.cn, Xing, Dongming^1,2,4 (AUTHOR) lxl2021910024@qdu.edu.cn

Publikováno v: Pharmaceutics. Oct2024, Vol. 16 Issue 10, p1255. 20p.

Unlocking the potential of bispecific ADCs for targeted cancer therapy.

Autor: Zeng H; State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, 361102, China.; National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Innovation Platform for Industry-Education Integration in Vaccine Research, the Research Unit of Frontier Technology of Structural Vaccinology of Chinese Academy of Medical Sciences, Xiamen University, Xiamen, 361102, China., Ning W; State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, 361102, China.; National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Innovation Platform for Industry-Education Integration in Vaccine Research, the Research Unit of Frontier Technology of Structural Vaccinology of Chinese Academy of Medical Sciences, Xiamen University, Xiamen, 361102, China., Liu X; State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, 361102, China. liuxue1108@xmu.edu.cn.; National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Innovation Platform for Industry-Education Integration in Vaccine Research, the Research Unit of Frontier Technology of Structural Vaccinology of Chinese Academy of Medical Sciences, Xiamen University, Xiamen, 361102, China. liuxue1108@xmu.edu.cn., Luo W; State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, 361102, China. wxluo@xmu.edu.cn.; National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Innovation Platform for Industry-Education Integration in Vaccine Research, the Research Unit of Frontier Technology of Structural Vaccinology of Chinese Academy of Medical Sciences, Xiamen University, Xiamen, 361102, China. wxluo@xmu.edu.cn., Xia N; State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, 361102, China.; National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Innovation Platform for Industry-Education Integration in Vaccine Research, the Research Unit of Frontier Technology of Structural Vaccinology of Chinese Academy of Medical Sciences, Xiamen University, Xiamen, 361102, China.

Publikováno v: Frontiers of medicine [Front Med] 2024 Aug; Vol. 18 (4), pp. 597-621. Date of Electronic Publication: 2024 Jul 23.

The Safety and Efficacy of the Combination of Sacituzumab Govitecan and Palliative Radiotherapy—A Retrospective Multi-Center Cohort Study.

Autor: Krug, David¹ (AUTHOR) david.krug@uksh.de, Tio, Joke² (AUTHOR) joke.tio@ukmuenster.de, Abaci, Ali³ (AUTHOR) abaci.ali@mh-hannover.de, Beurer, Björn⁴ (AUTHOR) bjoern.beurer@klinikumevb.de, Brügge, Sandra⁵ (AUTHOR) sandra.bruegge@uksh.de, Elsayad, Khaled⁶ (AUTHOR) khaled.elsayad@ukmuenster.de, Meixner, Eva⁷ (AUTHOR) eva.meixner@med.uni-heidelberg.de, Park-Simon, Tjoung-Won⁸ (AUTHOR) park-simon.tjoung-won@mh-hannover.de, Smetanay, Katharina⁹ (AUTHOR) katharina.smetanay@med.uni-heidelberg.de, Winkelmann, Franziska¹⁰ (AUTHOR) franziska.winkelmann@klinikumevb.de, Wittig, Andrea¹¹ (AUTHOR) wittig_a1@ukw.de, Wöckel, Achim¹² (AUTHOR) woeckel_a@ukw.de

Publikováno v: Cancers. May2024, Vol. 16 Issue 9, p1649. 12p.

Organelle resolved proteomics uncovers PLA2R1 as a novel cell surface marker required for chordoma growth.

Autor: Khan, Shahbaz¹ (AUTHOR), Zuccato, Jeffrey A.² (AUTHOR), Ignatchenko, Vladimir¹ (AUTHOR), Singh, Olivia¹ (AUTHOR), Govindarajan, Meinusha^1,3 (AUTHOR), Waas, Matthew¹ (AUTHOR), Mejia-Guerrero, Salvador¹ (AUTHOR), Gao, Andrew⁴ (AUTHOR), Zadeh, Gelareh^1,2 (AUTHOR), Kislinger, Thomas^1,3 (AUTHOR) thomas.kislinger@utoronto.ca

Publikováno v: Acta Neuropathologica Communications. 3/7/2024, Vol. 12 Issue 1, p1-17. 17p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.